Quantcast
Last updated on April 17, 2014 at 11:05 EDT

Latest Tanabe Research Laboratories U.S.A. Inc. Stories

2013-11-21 04:22:15

Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program ZURICH-SCHLIEREN, Switzerland and SAN DIEGO, Nov. 21, 2013 /PRNewswire/ -- Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have...

2012-10-17 03:20:59

ZURICH-SCHLIEREN, Switzerland, Oct. 17, 2012 /PRNewswire/ -- Covagen announced today that it has entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and its fully owned subsidiary Tanabe Research Laboratories U.S.A., Inc. of San Diego Calif. (TRL). Under the agreement, Covagen will use its proprietary Fynomer-antibody platform to generate bispecific proteins (FynomAbs) against two target pairs selected...

2011-10-04 07:15:00

WALTHAM, Mass., Oct. 4, 2011 /PRNewswire/ -- X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories U.S.A., Inc. (TRL). The companies will collaborate to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies to the identified therapeutic targets. X-BODY has developed an extremely diverse human antibody library and screens it using the company's proprietary Protein Chain Reaction(TM)....

2010-12-13 07:00:00

LA JOLLA, Calif., Dec. 13, 2010 /PRNewswire/ -- Anaphore Inc. today announced that the company has entered into a partnership with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) for the research, development and commercialization of novel protein therapies for autoimmune disease. The partnership will be based on Anaphore's proprietary platform technology, which generates novel trivalent proteins called Atrimers(TM) with binding domains that can be programmed to bind to and activate...

2010-12-13 07:00:00

SAN DIEGO, Dec. 13, 2010 /PRNewswire/ -- Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer(TM) technology. TRL and Anaphore will generate novel trivalent proteins called Atrimers that can be programmed to bind to and activate or inhibit targets of interest. The partnership will focus...